Senores Pharmaceuticals has debuted at Rs 593.70 on the BSE, up by 202.7 points or 51.84% from its issue price of Rs 391.00.
The scrip is currently trading at Rs 569.25, up by 178.25 points or 45.59% from its issue price.
It has touched a high and low of Rs 609.00 and Rs 566.85 respectively. So far 6.74 lakh shares were traded on the counter.
The offering, which was open for subscription between December 20, 2024 and December 24, 2024 was subscribed around 93 times. The issue price was fixed at Rs 391.00 per share i.e. at upper end of price band of Rs 372-391apiece.
Senores Pharmaceuticals is global research driven pharmaceutical company engaged in developing and manufacturing a wide range of generic pharmaceutical products in the B2B segment predominantly for the Regulated Markets across various therapeutic areas and dosage forms.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1834.40 |
| Dr. Reddys Lab | 1306.80 |
| Cipla | 1362.85 |
| Zydus Lifesciences | 940.10 |
| Lupin | 2459.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: